【摘要】 目的:探讨小剂量灯盏花素治疗胎儿生长受限(FGR)的临床疗效和安全性。方法:将170例FGR患者分为3组,即常规治疗组、灯盏花素组、复方丹参组。另有47例FGR患者未行药物治疗(对照组)。治疗前后监测胎儿生长情况及脐血流变化,同时监测肝肾功能、血浆内皮素水平;记录新生儿情况并进行随访。结果:①灯盏花素组与复方丹参组胎儿双顶径、股骨长、头围、腹围增大优于常规治疗组,且非常显著高于对照组(P<0.01)。②灯盏花素组与复方丹参组脐动脉血流显著低于对照组(P<0.05)。③灯盏花素组新生儿出生1minApgar评分、20项神经行为评分、出生体重、出生身长、出生头围均明显增加;胎龄也显著长于对照组,组间比较均有非常显著性差异(P<0.01)。④灯盏花素组足月小样儿1例,Apgar评分、新生儿20分项神经行为评分显著低于对照组,组间比较均有非常显著性差异(P<0.01)。⑤灯盏花素组新生儿出生后42天体重、身长、头围组间比较均有非常显著性差异(P<0.01)。⑥各组孕妇治疗前后肝肾功能,血浆内皮素值及新生儿脐带血查心肝肾功能比较,差异均无显著性(P>0.05)。结论:灯盏花素可改善胎盘血流,使胎儿体重增加,减少足月小样儿的发生,改善围产儿的预后,且灯盏花素治疗FGR对母、婴都较安全。更多还原

【Abstract】 Objective:To assess the efficacy and safety of Breviscapine in management of fetal growth restriction(FGR). Methods:170 cases of FGR were divided in study group,conventional group and control group at random.Another 47 cases just observed without therapy were in blank group. Energy-rich compound and amino acid compound 500ml was intravenous drip in 42 cases of the conventional group.Breviscapine 10mg in 10% Glucose liquid 500ml was intravenous drip in 4～6h in 77 cases of the study group,in addition to the same therapy recipe as conventional group.Injection Dan-Shen Root compound 16ml in Low Molecular Dextran 500ml was intravenous drip in 51 cases of the control group,in addition to the same therapy recipe as conventional group.The change of fetal growth and umbilical cord hemodynamics,materal and neonatal liver and kidney function and plasma endothelin before and after therapy was recorded.The neonates were followed up. Results: (1)Compared with the conventional group,the growth of fetal biparietal diameter,femur length,head circumference and abdomen circumference was better in the study group and the control group(P<0.05).They were much better than those of the blank group(P<0.01).(2)The value of umbilical artery S/D in the study group and the control group was significantly lower than that of the blank group(P <0.05).(3)The neonatal Apgar score,20 neonatal behavioral neurologic assessment score weight at birth,height at birth,head circumference at birth and gestational week were better than blank group(P<0.01).(4)In study group,1 case low birth weight infant,neonatal Apgar score,and 20 neonatal behavioral neurologic assessment score were lower than the blank group(P< 0.01).(5)42 days after birth,the neonatal in study group weight,height and his head circumference were better than blank group(P<0.01).(6)There wasn′t significant difference among the change of materal and neonatal liver and kidney function and plasma endothelin before and after therapy of all pregnant women in each group(P> 0.05).Conclusion : It’s safe and effective to treat fetal growth restriction with Breviscapine.It could improve placental perfusion to increase fetal weight,reduce the frequence of low birth weight infant,and improve prognosis of perinatal outcomes.更多还原